Adaptive biotechnologies announces over 65 abstracts featuring clonoseq® mrd testing across a range of blood cancers to be presented at the 66th ash annual meeting

Seattle, dec. 03, 2024 (globe newswire) -- adaptive biotechnologies corporation (nasdaq: adpt), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced that its next-generation sequencing (ngs)-based clonoseq® test for measurable residual disease (mrd) assessment will be included in more than 65 abstracts across eight different types of blood cancer at the 66th annual meeting of the american society of hematology (ash) taking place december 7-10, 2024, in san diego. among these abstracts are a plenary session presentation, a late-breaking abstract and 25 other oral presentations.
ASH Ratings Summary
ASH Quant Ranking